Marker Therapeutics ((MRKR)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Marker Therapeutics is conducting a Phase 1 study titled ‘A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO).’ The study aims to assess the safety and preliminary efficacy of MT-601 in patients with relapsed or refractory lymphoma, a significant step in advancing treatment options for these conditions.
The intervention being tested is MT-601, a drug composed of multi-antigen specific CD4+ and CD8+ T cells. It is designed to target and treat lymphoma by enhancing the body’s immune response to cancer cells.
This interventional study follows a single-group model with no masking, focusing on treatment as its primary purpose. It involves a dose escalation and expansion to evaluate the safety and efficacy of MT-601, with doses starting at 200 million cells.
The study began on March 14, 2023, and is currently recruiting participants. The last update was submitted on August 14, 2025. These dates are crucial as they indicate the study’s progress and the timeline for potential results.
The update on this study could positively influence Marker Therapeutics’ stock performance by boosting investor confidence, especially if preliminary results show promise. It also positions the company competitively within the biotech industry, which is rapidly evolving with new cancer therapies.
The study is ongoing, with further details available on the ClinicalTrials portal.